Visit the NEW CoM Homepage |  University of Kentucky |  UK HealthCare |  Give to Medicine |  Diversity  
UK College of Medicine logo Link to the College of Medicine web site
  • ed2
  • rs1
  • cs5
  • ad1

Internal Medicine - Endocrinology

INTERNAL MEDICINE

Endocrinology

BARNSTABLE BROWN OBESITY AND DIABETES RESEARCH DAY

CONTACT

Lisa R. Tannock, M.D.

Picture of Dr. Tannock   
   

          Chief, Division of Endocrinology and Molecular Medicine
          Associate Professor, Division of Endocrinology and Molecular Medicine
          Associate Director, Barnstable Brown Kentucky Diabetes and Obesity Center
          Core Faculty Member, Saha Cardiovascular Research Center


         Best Doctors logo



 

Contact Information

Training and Publications

University of Kentucky
567 Charles T. Wethington Building Publication Listing on PubMed
900 South Limestone Street
Lexington, KY 40536-0200  
Telephone: (859) 323-5821  
FOR PATIENT INQUIRIES PLEASE CALL : (859) 323-2232  
Fax: (859) 323-5707  
 

Clinical Interests

Dr. Tannock is an Endocrinologist who sees patients with diabetes and other Endocrinology disorders.

 

Research Topics

Hyperlipidemia
Mechanisms underlying atherosclerosis development
Hyperlipidemia and diabetic nephropathy
Inflammation in metabolic syndrome, obesity and diabetes

 

Research Interests

Proteoglycans have been shown to play a critical role in the initiation of atherosclerosis due to their ability to bind atherogenic lipoproteins leading to retention in the artery wall, as outlined in the “response to retention hypothesis”. Research in Dr. Tannock's laboratory aims to identify the role of proteoglycans in the pathogenesis of complications of diabetes and obesity, including atherosclerosis and nephropathy. Current studies are using angiotensin II to regulate vascular proteoglycans in animal models of diabetes, obesity, and atherosclerosis. Related studies are examining the interaction between inflammatory mediators/ markers and vascular proteoglycans. Subjects with obesity, metabolic syndrome or diabetes have modest but chronic elevations in levels of the acute phase reactants C reactive protein (CRP) and serum amyloid A (SAA). Dr Tannock has recently demonstrated that SAA alters vascular proteoglycan synthesis in a pro-atherogenic manner, suggesting that the modest chronically elevated levels of SAA seen in obese individuals could mechanistically contribute to atherosclerosis development. In addition, recent research demonstrates that hyperlipidemia can adversely contribute to the development of diabetic nephropathy, a process that may be mediated via renal accumulation of lipoproteins. The role of renal proteoglycans in the development of diabetic nephropathy is another topic of investigation. A major focus of the lab is to identify the underlying mechanisms that regulate proteoglycan synthesis and subsequently influence proteoglycan-lipoprotein interactions. Results from these studies will advance our understanding of the mechanisms of atherosclerosis, and may identify novel therapeutic targets to decrease lipoprotein retention as a strategy to prevent complications of diabetes and obesity.

Comments and Corrections |  An Equal Opportunity University |  Jobs  |  Terms, Conditions and Accessibility Statements   |  Privacy
© 2012, University of Kentucky College of Medicine, 138 Leader Ave., Lexington, Kentucky, USA 40506-9983
Student Affairs: (859) 323-5261 · Admissions: (859) 323-6161 · Clinical Questions: (859) 257-1000 · Dean's Office: (859) 323-6582
Page last updated Tuesday, December 04, 2012